Corporate GovernanceJul 17, 2026, 04:07 PM
Evogene faces activist demand to remove most board members
AI Summary
Evogene Ltd. increased the maximum aggregate offering price of its at-the-market offering by $361,613 to $3,288,113. Concurrently, the company updated its risk factors to address an ongoing shareholder activism campaign. Activist shareholders are demanding an extraordinary general meeting to remove all current board members, excluding the CEO, and replace them with their own nominees, posing significant risks to the company's operations and stability.
Key Highlights
- Increased at-the-market offering by $361,613, raising the maximum to $3,288,113.
- Shareholder activism campaign initiated by Schedule 13D filers on July 10, 2026.
- Activists demand an extraordinary general meeting to remove all current board members except the CEO.
- Campaign could divert significant management time and resources from core R&D efforts.
- Potential to discourage strategic partners and damage long-term business relationships.
- Risk of increased share price volatility and difficulty in raising capital.
- Significant board change could disrupt strategy and lead to loss of key personnel.
- Demands may implicate U.S. federal securities laws and Israeli corporate law.
Price Impact
More from EVGN